NIDA-CTO-0007
Division
HEAL Study
Investigator(s)
Title
Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence
Short Description
To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that cabergoline treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).
Release Date
Dec 21, 2017
Description
The primary objective of this study is to assess the efficacy of cabergoline in reducing cocaine use in subjects with cocaine dependence (DSM-IV criteria). The hypothesis is that cabergoline will increase the weekly mean proportion of cocaine non-use days over the treatment period as compared to placebo as determined by self-report of cocaine use confirmed with urine assays for BE.
Keywords
Accessibility Notice
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.